Key Highlights

  • Jupiter Neurosciences secured exclusive U.S. rights to PharmAla's patented non-racemic MDMA formulation ALA-002.
  • The deal gives Jupiter a psychedelic neuropsychiatric asset.
  • PharmAla retains Downstream Economics and full ownership of APA-01.
  • A separate proposed Restora licensing structure was canceled as part of the arrangement.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) secured exclusive U.S. rights to PharmAla's patented non-racemic MDMA formulation ALA-002, giving Jupiter a psychedelic neuropsychiatric asset.

What Happened

PharmAla retains downstream economics and full ownership of APA-01 after canceling a separate proposed Restora licensing structure.

Market Reaction

The disclosed information does not include stock price or trading data for Jupiter Neurosciences following the licensing announcement.

Outlook

Continued development plans for ALA-002 in neuropsychiatric indications represent the next disclosed focus area for Jupiter Neurosciences following this licensing agreement.